KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

FRA:PHI1 • NL0000009538

26.59 EUR
+0.44 (+1.68%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

PHI1 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 67 industry peers in the Health Care Equipment & Supplies industry. PHI1 may be in some trouble as it scores bad on both profitability and health. PHI1 has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • PHI1 had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • PHI1's Return On Assets of 3.32% is in line compared to the rest of the industry. PHI1 outperforms 46.27% of its industry peers.
  • PHI1's Return On Equity of 8.17% is in line compared to the rest of the industry. PHI1 outperforms 56.72% of its industry peers.
  • PHI1's Return On Invested Capital of 5.16% is in line compared to the rest of the industry. PHI1 outperforms 40.30% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PHI1 is significantly below the industry average of 9.66%.
  • The last Return On Invested Capital (5.16%) for PHI1 is above the 3 year average (3.24%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • PHI1 has a Profit Margin (5.02%) which is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of PHI1 has declined.
  • The Operating Margin of PHI1 (7.98%) is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of PHI1 has declined.
  • Looking at the Gross Margin, with a value of 45.18%, PHI1 is doing worse than 73.13% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHI1 is destroying value.
  • Compared to 1 year ago, PHI1 has more shares outstanding
  • The number of shares outstanding for PHI1 has been increased compared to 5 years ago.
  • Compared to 1 year ago, PHI1 has a worse debt to assets ratio.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • The Debt to FCF ratio of PHI1 is 16.37, which is on the high side as it means it would take PHI1, 16.37 years of fcf income to pay off all of its debts.
  • PHI1 has a worse Debt to FCF ratio (16.37) than 62.69% of its industry peers.
  • A Debt/Equity ratio of 0.63 indicates that PHI1 is somewhat dependend on debt financing.
  • PHI1 has a worse Debt to Equity ratio (0.63) than 70.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z N/A
ROIC/WACC0.8
WACC6.47%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.32, PHI1 is doing worse than 61.19% of the companies in the same industry.
  • PHI1 has a Quick Ratio of 1.32. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.94, PHI1 is not doing good in the industry: 65.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.45%, which is quite good.
  • The Earnings Per Share has been decreasing by -5.53% on average over the past years.
  • The Revenue has decreased by -1.04% in the past year.
  • The Revenue has been growing slightly by 0.59% on average over the past years.
EPS 1Y (TTM)12.45%
EPS 3Y17.92%
EPS 5Y-5.53%
EPS Q2Q%15.25%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%-1.22%

3.2 Future

  • PHI1 is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.17% yearly.
  • The Revenue is expected to grow by 3.79% on average over the next years.
EPS Next Y-2.32%
EPS Next 2Y5.02%
EPS Next 3Y13.51%
EPS Next 5Y7.17%
Revenue Next Year2.83%
Revenue Next 2Y3.55%
Revenue Next 3Y4.91%
Revenue Next 5Y3.79%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.04, the valuation of PHI1 can be described as rather expensive.
  • Based on the Price/Earnings ratio, PHI1 is valued cheaper than 85.07% of the companies in the same industry.
  • PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.27.
  • The Price/Forward Earnings ratio is 17.47, which indicates a rather expensive current valuation of PHI1.
  • Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than 61.19% of the companies in the same industry.
  • PHI1's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.16.
Industry RankSector Rank
PE 17.04
Fwd PE 17.47
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHI1 is valued a bit cheaper than 70.15% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 51.83
EV/EBITDA 12.12
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PHI1's earnings are expected to grow with 13.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.02%
EPS Next 3Y13.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KONINKLIJKE PHILIPS NV

FRA:PHI1 (2/18/2026, 7:00:00 PM)

26.59

+0.44 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap25.60B
Revenue(TTM)17.83B
Net Income(TTM)895.00M
Analysts73.33
Price Target27.26 (2.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.15%
Min EPS beat(2)14.1%
Max EPS beat(2)22.2%
EPS beat(4)4
Avg EPS beat(4)22.4%
Min EPS beat(4)14.1%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)5.12%
EPS beat(12)6
Avg EPS beat(12)7.99%
EPS beat(16)7
Avg EPS beat(16)8.07%
Revenue beat(2)0
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-2.82%
Max Revenue beat(2)-2.4%
Revenue beat(4)0
Avg Revenue beat(4)-2.29%
Min Revenue beat(4)-2.82%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-2.85%
Revenue beat(12)1
Avg Revenue beat(12)-2.52%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)-1.52%
PT rev (3m)-0.19%
EPS NQ rev (1m)-15.5%
EPS NQ rev (3m)-15.5%
EPS NY rev (1m)-0.33%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)3.12%
Revenue NQ rev (3m)3.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.59%
Valuation
Industry RankSector Rank
PE 17.04
Fwd PE 17.47
P/S 1.44
P/FCF 51.83
P/OCF 22.03
P/B 2.34
P/tB N/A
EV/EBITDA 12.12
EPS(TTM)1.56
EY5.87%
EPS(NY)1.52
Fwd EY5.72%
FCF(TTM)0.51
FCFY1.93%
OCF(TTM)1.21
OCFY4.54%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number19.99
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
ROICexc(3y)3.72%
ROICexc(5y)N/A
ROICexgc(3y)12.84%
ROICexgc(5y)N/A
ROCE(3y)4.62%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.31%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.82%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z N/A
F-Score7
WACC6.47%
ROIC/WACC0.8
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.45%
EPS 3Y17.92%
EPS 5Y-5.53%
EPS Q2Q%15.25%
EPS Next Y-2.32%
EPS Next 2Y5.02%
EPS Next 3Y13.51%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%-1.22%
Revenue Next Year2.83%
Revenue Next 2Y3.55%
Revenue Next 3Y4.91%
Revenue Next 5Y3.79%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-5.03%
EBIT Next Year63.55%
EBIT Next 3YN/A
EBIT Next 5Y17.05%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 3 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 1 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 36.65%.